Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26692937 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL3484762 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL3484909 | 0.98 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL26692883 | 0.98 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL3484910 | 0.98 | CYP3A4 (0.55) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL3484864 | 0.97 | CYP3A4 (0.57) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL3484865 | 0.97 | CYP3A4 (0.57) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL26692896 | 0.97 | CYP3A4 (0.57) | CYP3A4CYP2C9BTN3A1ADKNT5E | |
| SCHEMBL930688 | 0.91 | CYP3A4 (0.53) | CYP3A4CYP2C9BTN3A1NT5E | |
| SCHEMBL930689 | 0.91 | CYP3A4 (0.53) | CYP3A4CYP2C9BTN3A1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288020-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-09-25 | — | — | US | claimed |
| EP-2203462-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | Pharmasset, Inc. (US) | 2010-07-07 | — | — | EP | claimed |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2010-01-21 | — | — | US | claimed |
| WO-2008121634-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| EP-2933260-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | Gilead Pharmasset LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2826784-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2824109-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2801580-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2792680-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2014-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | CYP3A4 1268/4885CYP2C9 868/4885BTN3A1 4740/4885 |
| US-20140288020-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | CYP3A4 1268/4885CYP2C9 868/4885BTN3A1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.